Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6

Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into pathways that may contribute to the divergent sensitivity t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Andrew W., Kozielski, Anthony J., Qian, Wei, Zhou, Jianying, Anselme, Ann C., Chan, Alfred A., Pan, Ping-Ying, Lee, Delphine J., Chang, Jenny C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904846/
https://www.ncbi.nlm.nih.gov/pubmed/35260569
http://dx.doi.org/10.1038/s41523-021-00371-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904846/
https://www.ncbi.nlm.nih.gov/pubmed/35260569
http://dx.doi.org/10.1038/s41523-021-00371-0

Ejemplares similares